From: Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women
 |  |  |  | % of Cases Estimated to be Attributable to Specific HPV types |  | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Year | Author | N | Testing Method | HPV 6 | HPV 11 | HPV 16 | HPV 18 | HPV 31 | HPV 33 | HPV 45 | HPV 52 | HPV 58 | Any HPV type* |
CIN 1 30,31,39–41,43 |  |  |  |  |  |  |  |  |  |  |  |  |  |
2006 | Srodon, M | 36 | PCR/Biopsy | 2.8 | 2.8 | 11.1 | 16.7 | 5.6 | 5.6 | 5.6 | 2.8 | 2.8 | 100.0 |
2005 | Hu, L†| 45 | PCR/Biopsy |  |  | 6.4 | 2.2 | 3.1 | 0.0 | 2.2 | 12.2 | 7.2 | 87.0 |
2002 | Evans, M†| 28 | PCR/Biopsy | 4.5 | 3.6 | 7.1 | 3.6 | 7.1 | 3.6 | 3.6 | 7.1 | 0.0 | 100.0 |
1998 | Aoyama, C | 11 | PCR/Biopsy | 0.0 | 0.0 | 27.3 | 9.1 | 9.1 | 9.1 | Â | Â | Â | 54.5 |
1998 | Quade, B | 30 | PCR/Biopsy | 3.3 | 3.3 | 10.0 | 3.3 | 6.7 | 0.0 | 0.0 | 0.0 | 0.0 | 73.3 |
1996 | Isacson, C | 40 | PCR/Biopsy | 5.0 | 10.0 | Â | Â | Â | Â | Â | Â | Â | Â |
Total | Â | 190 | Â | 3.6 | 4.8 | 9.9 | 6.7 | 5.6 | 2.7 | 2.9 | 6.1 | 3.0 | 87.4 |
CIN 2/3 30,31,39–43 |  |  |  |  |  |  |  |  |  |  |  |  |  |
2006 | Srodon, M | 116 | PCR/Biopsy | 0.0 | 0.0 | 75.0 | 4.3 | 5.2 | 1.7 | 0.0 | 0.9 | 3.4 | 100.0 |
2005 | Hu, L†| 97 | PCR/Biopsy |  |  | 38.9 | 9.6 | 11.6 | 1.0 | 1.1 | 5.0 | 2.6 | 93.6 |
2002 | Evans, M | 22 | PCR/Biopsy | 0.0 | 0.0 | 68.2 | 4.5 | 9.1 | 4.5 | 4.5 | 0.0 | 4.5 | 100.0 |
1998 | Aoyama, C | 21 | PCR/Biopsy | 0.0 | 0.0 | 52.4 | 0.0 | 19.0 | 19.0 | Â | Â | Â | 95.2 |
1998 | Quade, B | 19 | PCR/Biopsy | 0.0 | 0.0 | 52.6 | 5.3 | 0.0 | 15.8 | 0.0 | 0.0 | 0.0 | 78.9 |
1996 | Isacson, C | 11 | PCR/Biopsy | 0.0 | 0.0 | 45.5 | 0.0 | 18.2 | 9.1 | 0.0 | 0.0 | 0.0 | 100.0 |
1993 | Shroyer, K | 13 | PCR/Biopsy | 0.0 | 0.0 | 61.5 | 0.0 | Â | Â | Â | Â | Â | 92.3 |
Total | Â | 299 | Â | 0.0 | 0.0 | 58.1 | 5.5 | 8.8 | 4.2 | 0.8 | 2.2 | 2.8 | 95.9 |